Sign Up for Free!

Continue Analyzing the page and more.

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Regencell Bioscience Holdings Ltd logo
RGC

Regencell Bioscience Holdings Ltd

MaveScore 9 Low model confidence
Last Price US$17.09 As of Jun 15, 2026
Market Cap US$8.5b Company size context
7D Performance -20.86% Past 7 days
1Y Performance -96.61% Past 12 months
Model Rating
Historical model output for research review

Fundamental data date

Updating

Refreshing

Market price date

Jun 15, 2026

1 day old

Coverage

10/16

6 missing model inputs

Data quality

Review

Partial or delayed snapshot

Transparent research score

Why the model scores this stock

MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

MaveScore 9 Low confidence

Stored data quality

Freshness and coverage checks

Stored company inputs are available, but some dates or model fields are older or incomplete.

10/16 Partial or delayed snapshot

Quality

Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

6/35 Weak

Financial Strength

Financial strength needs live profitability and cash-flow fields.

0/25 Needs Data

Valuation Support

Valuation needs price plus per-share earnings, cash-flow, or book-value inputs.

0/15 Needs Data

Momentum

Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

3/15 Weak

Shareholder Alignment

Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

0/10 Weak

Positive model output

More live company inputs are needed before positive research signals can be surfaced.

Research risks to review

  • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
  • Financial strength needs live profitability and cash-flow fields.
  • Valuation needs price plus per-share earnings, cash-flow, or book-value inputs.

MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include return on equity, net margin, gross margin, free cash flow per share, book value per share, earnings per share.

Dashboard Funda..tals Deep..lue Prediction Screener Map

Regencell Bioscience Holdings Ltd Overview

Industry: Drug Manufacturers Specialty & Generic

Sector: Healthcare

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Regencell Bioscience Holdings Ltd is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

Score

Price History & Performance

Review Regencell Bioscience Holdings Ltd in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

Recent News



Regencell Bioscience Holdings Ltd Competitors

Regencell Bioscience Holdings Ltd operates in the Drug Manufacturers Specialty & Generic industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

Earnings Per Share

EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

Continue the analysis

Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

View plans
Ticker Image

Regencell Bioscience Holdings Ltd

US$17.09

US$8.5b

-20.86%

-96.61%